Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST11-mediated VTP in obstructing endobronchial NSCLC
NCT00974662Phase 2Terminated
- Sponsor
- Steba Biotech
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of padeliporfin VTP in non-small cell lung cancer (NSCLC), sponsored by Steba Biotech. Primary endpoint: Percentage of bronchial obstruction at 1 month. Started Sep 2009; status: terminated.
02
Drugs
padeliporfin VTP
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00974662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00974662.